Treatment planning for children with attention-deficit/hyperactivity disorder: Treatment utilization and family preferences

Patient Preference and Adherence

Volumn 5, Issue , 2011, Pages 45-56

  Brinkman, William B ^a   Epstein, Jeffery N ^a  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

Author keywords

ADHD; Adherence; Attention deficit hyperactivity disorder; Collaborative shared decision making; Physician patient parent communication; Preferences

Indexed keywords

DEXAMPHETAMINE; METHYLPHENIDATE; PLACEBO;

ATTENTION DEFICIT DISORDER; BEHAVIOR THERAPY; CAREGIVER; CLINICAL EFFECTIVENESS; COST BENEFIT ANALYSIS; CULTURAL FACTOR; DECISION MAKING; DOCTOR PATIENT RELATION; DRUG COST; DRUG DOSE TITRATION; EARLY CHILDHOOD INTERVENTION; FAMILY ATTITUDE; HEALTH CARE UTILIZATION; HUMAN; PARENTAL ATTITUDE; PATIENT COMPLIANCE; PSYCHOSOCIAL CARE; QUALITATIVE RESEARCH; QUANTITATIVE STUDY; REVIEW; RISK BENEFIT ANALYSIS; SYSTEMATIC REVIEW; TREATMENT PLANNING; UNSPECIFIED SIDE EFFECT;

EID: 84856451502     PISSN: None     EISSN: 1177889X     Source Type: Journal    
DOI: 10.2147/PPA.S10647     Document Type: Review

References (109)

1. Froehlich TE, Lanphear BP, Epstein JN, Barbaresi WJ, Katusic SK, Kahn RS. Prevalence, recognition, and treatment of attention-deficit/ hyperactivity disorder in a national sample of US children. Arch Pediatr Adolesc Med. 2007;161(9):857-864
2. The MTA Cooperative Group. A 14-month randomized clinical trial of treatment strategies for attention-deficit/hyperactivity disorder. Arch Gen Psychiatry. 1999;56(12):1073-1086
3. American Academy of Pediatrics. Subcommittee on Attention-Deficit/ Hyperactivity Disorder and Committee on Quality Improvement. Clinical practice guideline: treatment of the school-aged child with attention-deficit/ hyperactivity disorder. Pediatrics. 2001;108(4):1033-1044
4. Pliszka S. AACAP Work Group on Quality Issues. Practice parameter for the assessment and treatment of children and adolescents with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry. 2007;46(7):894-921
5. Chan E, Rappaport LA, Kemper KJ. Complementary and alternative therapies in childhood attention and hyperactivity problems. J Dev Behav Pediatr. 2003;24(1):4-8
6. Johnston C, Seipp C, Hommersen P, Hoza B, Fine S. Treatment choices and experiences in attention deficit and hyperactivity disorder: relations to parents' beliefs and attributions. Child Care Health Dev. 2005;31(6):669-677
7. Concannon PE, Tang YP. Management of attention deficit hyperactivity disorder: a parental perspective. J Paediatr Child Health. 2005;41(12): 625-630
8. Rucklidge JJ, Johnstone J, Kaplan BJ. Nutrient supplementation approaches in the treatment of ADHD. Expert Rev Neurother. 2009; 9(4):461-476
9. Swanson JM, Kraemer HC, Hinshaw SP, et al. Clinical relevance of the primary findings of the MTA: success rates based on severity of ADHD and ODD symptoms at the end of treatment. J Am Acad Child Adolesc Psychiatry. 2001;40(2):168-179
10. Pelham WE Jr, Fabiano GA. Evidence-based psychosocial treatments for attention-deficit/hyperactivity disorder. J Clin Child Adolesc Psychol. 2008;37(1):184-214
11. Barkley RA, Shelton TL, Crosswait C, et al. Multi-method psychoeducational intervention for preschool children with disruptive behavior: preliminary results at post-treatment. J Child Psychol Psychiatry. 2000;41(3):319-332
12. Bussing R, Zima BT, Belin TR. Variations in ADHD treatment among special education students. J Am Acad Child Adolesc Psychiatry. 1998;37(9):968-976
13. The MTA Cooperative Group. Moderators and mediators of treatment response for children with attention-deficit/hyperactivity disorder: the Multimodal Treatment Study of children with attention-deficit/hyperactivity disorder. Arch Gen Psychiatry. 1999;56(12):1088-1096
14. Greenhill LL, Swanson JM, Vitiello B, et al. Impairment and deportment responses to different methylphenidate doses in children with ADHD: the MTA titration trial. J Am Acad Child Adolesc Psychiatry. 2001;40(2):180-187
15. Vitiello B, Severe JB, Greenhill LL, et al. Methylphenidate dosage for children with ADHD over time under controlled conditions: lessons from the MTA. J Am Acad Child Adolesc Psychiatry. 2001;40(2):88-196
16. Epstein JN, Rabiner D, Johnson DE, et al. Improving attention-deficit/ hyperactivity disorder treatment outcomes through use of a collaborative consultation treatment service by community-based pediatricians: a cluster randomized trial. Arch Pediatr Adolesc Med. 2007;161(9): 835-840
17. Pappadopulos E, Jensen PS, Chait AR, et al. Medication adherence in the MTA: saliva methylphenidate samples versus parent report and mediating effect of concomitant behavioral treatment. J Am Acad Child Adolesc Psychiatry. 2009;48(5):501-510
18. Hudson JL, Miller GE, Kirby JB. Explaining racial and ethnic differences in children's use of stimulant medications. Med Care. 2007; 45(11):1068-1075
19. Centers for Disease Control and Prevention (CDC). Mental health in the United States. Prevalence of diagnosis and medication treatment for attention-deficit/hyperactivity disorder - United States, 2003. MMWR Morb Mortal Wkly Rep. 2005;54(34):842-847
20. Marcus SC, Wan GJ, Kemner JE, Olfson M. Continuity of methylphenidate treatment for attention-deficit/hyperactivity disorder. Arch Pediatr Adolesc Med. 2005;159(6):572-578
21. Sanchez RJ, Crismon ML, Barner JC, Bettinger T, Wilson JP. Assessment of adherence measures with different stimulants among children and adolescents. Pharmacotherapy. 2005;25(7):909-917
22. Bokhari FAS, Heiland F, Levine P, Ray GT. Risk factors for discontinuing drug therapy among children with ADHD. Health Serv Outcomes Res Methodol. 2008;8(3):134-158
23. Wennberg JE, Fisher ES, Skinner JS. Geography and the debate over Medicare reform. Health Aff (Millwood). 2002;Suppl Web Exclusives: W96-W114.
24. Kazdin AE. Acceptability of alternative treatments for deviant child behavior. J Appl Behav Anal. 1980;13(2):259-273
25. Liu C, Robin AL, Brenner S, Eastman J. Social acceptability of methylphenidate and behavior modification for treating attention deficit hyperactivity disorder. Pediatrics. 1991;88(3):560-565
26. Gage JD, Wilson LJ. Acceptability of attention-deficit/hyperactivity disorder interventions: a comparison of parents. J Atten Disord. 2000; 4(3):174-182
27. Johnston C, Fine S. Methods of evaluating methylphenidate in children with attention deficit hyperactivity disorder: acceptability, satisfaction, and compliance. J Pediatr Psychol. 1993;18(6):717-730
28. Johnston C, Hommersen P, Seipp C. Acceptability of behavioral and pharmacological treatments for attention-deficit/hyperactivity disorder: relations to child and parent characteristics. Behav Ther. 2008;39(1): 22-32
29. Krain AL, Kendall PC, Power TJ. The role of treatment acceptability in the initiation of treatment for ADHD. J Atten Disord. 2005;9(2): 425-434
30. Rostain AL, Power TJ, Atkins MS. Assessing parents' willingness to pursue treatment for children with attention-deficit hyperactivity disorder. J Am Acad Child Adolesc Psychiatry. 1993;32(1):175-181
31. Corkum P, Rimer P, Schachar R. Parental knowledge of attention- deficit hyperactivity disorder and opinions of treatment options: impact on enrollment and adherence to a 12-month treatment trial. Can J Psychiatry. 1999;44(10):1043-1048
32. Bennett DS, Power TJ, Rostain AL, Carr DE. Parent acceptability and feasibility of ADHD interventions: assessment, correlates, and predictive validity. J Pediatr Psychol. 1996;21(5):643-657
33. Bussing R, Gary FA, Mills TL, Garvan CW. Parental explanatory models of ADHD: gender and cultural variations. Soc Psychiatry Psychiatr Epidemiol. 2003;38(10):563-575
34. Leslie LK, Plemmons D, Monn AR, Palinkas LA. Investigating ADHD treatment trajectories: listening to families' stories about medication use. J Dev Behav Pediatr. 2007;28(3):179-188
35. Brinkman WB, Sherman SN, Zmitrovich AR, et al. Parental angst making and revisiting decisions about treatment of attention-deficit/ hyperactivity disorder. Pediatrics. 2009;124(2):580-589
36. Charach A, Skyba A, Cook L, Antle BJ. Using stimulant medication for children with ADHD: what do parents say? A brief report. J Can Acad Child Adolesc Psychiatry. 2006;15(2):75-83
37. DosReis S, Mychailyszyn MP, Evans-Lacko SE, Beltran A, Riley AW, Myers MA. The meaning of attention-deficit/hyperactivity disorder medication and parents' initiation and continuity of treatment for their child. J Child Adolesc Psychopharmacol. 2009;19(4): 377-383
38. Wolraich ML, Wilson DB, White JW. The effect of sugar on behavior or cognition in children. A meta-analysis. JAMA. 1995;274(20): 1617-1621
39. Bussing R, Gary FA. Practice guidelines and parental ADHD treatment evaluations: friends or foes? Harv Rev Psychiatry. 2001;9(5): 223-233
40. Bussing R, Zima BT, Gary FA, Garvan CW. Use of complementary and alternative medicine for symptoms of attention-deficit hyperactivity disorder. Psychiatr Serv. 2002;53(9):1096-1102
41. Bussing R, Schoenberg NE, Perwien AR. Knowledge and information about ADHD: evidence of cultural differences among African-American and white parents. Soc Sci Med. 1998;46(7):919-928
42. DosReis S, Zito JM, Safer DJ, Soeken KL, Mitchell JW Jr, Ellwood LC. Parental perceptions and satisfaction with stimulant medication for attention-deficit hyperactivity disorder. J Dev Behav Pediatr. 2003; 24(3):155-162
43. DosReis S, Butz A, Lipkin PH, Anixt JS, Weiner CL, Chernoff R. Attitudes about stimulant medication for attention-deficit/hyperactivity disorder among African American families in an inner city community. J Behav Health Serv Res. 2006;33(4):423-430
44. Henker B, Whalen CK. The many messages of medication: hyperactive children's perceptions and attributions. In: Salzinger S, Antrobus J, Glick J, editors. The Ecosystem of the "Sick" Child. New York (NY): Academic Press, Inc; 1980.
45. Hansen DL, Hansen EH. Caught in a balancing act: parents' dilemmas regarding their ADHD child's treatment with stimulant medication. Qual Health Res. 2006;16(9):1267-1285
46. Nikles CJ, Clavarino AM, Del Mar CB. Using n-of-1 trials as a clinical tool to improve prescribing. Br J Gen Pract. 2005;55(512): 175-180
47. Kent MA, Camfield CS, Camfield PR. Double-blind methylphenidate trials: practical, useful, and highly endorsed by families. Arch Pediatr Adolesc Med. 1999;153(12):1292-1296
48. Pliszka SR, Lopez M, Crismon ML, et al. A feasibility study of the children's medication algorithm project (CMAP) algorithm for the treatment of ADHD. J Am Acad Child Adolesc Psychiatry. 2003;42(3): 279-287
49. Mühlbacher AC, Rudolph I, Lincke HJ, Nübling M. Preferences for treatment of attention-deficit/hyperactivity disorder (ADHD): a discrete choice experiment. BMC Health Serv Res. 2009;9:149.
50. Bull C, Whelan T. Parental schemata in the management of children with attention deficit-hyperactivity disorder. Qual Health Res. 2006;16(5): 664-678
51. Berger I, Dor T, Nevo Y, Goldzweig G. Attitudes toward attention- deficit hyperactivity disorder (ADHD) treatment: parents' and children's perspectives. J Child Neurol. 2008;23(9):1036-1042
52. The MTA Cooperative Group. National Institute of Mental Health Multimodal Treatment Study of ADHD follow-up: changes in effectiveness and growth after the end of treatment. Pediatrics. 2004; 113(4):762-769
53. Swanson JM, Hinshaw SP, Arnold LE, et al. Secondary evaluations of MTA 36-month outcomes: propensity score and growth mixture model analyses. J Am Acad Child Adolesc Psychiatry. 2007;46(8):1003-1014
54. Nissen SE. ADHD drugs and cardiovascular risk. N Engl J Med. 2006; 354(14):1445-1448
55. Perrin JM, Friedman RA, Knilans TK. Black Box Working Group. Cardiovascular monitoring and stimulant drugs for attention-deficit/ hyperactivity disorder. Pediatrics. 2008;122(2):451-453
56. Vetter VL, Elia J, Erickson C, et al. Cardiovascular monitoring of children and adolescents with heart disease receiving medications for attention deficit/hyperactivity disorder [corrected]: a scientific statement from the American Heart Association Council on Cardiovascular Disease in the Young Congenital Cardiac Defects Committee and the Council on Cardiovascular Nursing. Circulation. 2008;117(18):2407-2423
57. Wilens TE, Prince JB, Spencer TJ, Biederman J. Stimulants and sudden death: what is a physician to do? Pediatrics. 2006;118(3): 1215-1219
58. Biederman J, Spencer TJ, Wilens TE, Prince JB, Faraone SV. Treatment of ADHD with stimulant medications: response to Nissen perspective in the New England Journal of Medicine. J Am Acad Child Adolesc Psychiatry. 2006;45(10):1147-1150
59. Olfson M, Gameroff MJ, Marcus SC, Jensen PS. National trends in the treatment of attention deficit hyperactivity disorder. Am J Psychiatry. 2003;160(6):1071-1077
60. Stevens J, Harman JS, Kelleher KJ. Race/ethnicity and insurance status as factors associated with ADHD treatment patterns. J Child Adolesc Psychopharmacol. 2005;15(1):8-96
61. Harborne A, Wolpert M, Clare L. Making sense of ADHD: a battle for understanding? Parents' views of their children being diagnosed with ADHD. Clin Child Psychol Psychiatry. 2004;9(3):327-339
62. Klasen H. A name, what's in a name? The medicalization of hyperactivity, revisited. Harv Rev Psychiatry. 2000;7(6):334-344
63. Malacrida C. Medicalization, ambivalence and social control: mothers' descriptions of educators and ADD/ADHD. Health (London). 2004; 8(1):61-80
64. Bussing R, Zima BT, Belin TR. Differential access to care for children with ADHD in special education programs. Psychiatr Serv. 1998;49(9): 1226-1229
65. Singh I. Doing their jobs: mothering with Ritalin in a culture of motherblame. Soc Sci Med. 2004;59(6):193-1205
66. Singh I. Boys will be boys: fathers' perspectives on ADHD symptoms, diagnosis, and drug treatment. Harv Rev Psychiatry. 2003;11(6): 308-316
67. Baxley GB, Turner PF, Greenwold WE. Hyperactive children's knowledge and attitudes concerning drug treatment. J Pediatr Psychol. 1978;3(4):172-176
68. Arcia E, Fernández MC, Jáquez M. Latina mothers' stances on stimulant medication: complexity, conflict, and compromise. J Dev Behav Pediatr. 2004;25(5):311-317
69. Perry CE, Hatton D, Kendall J. Latino parents' accounts of attention deficit hyperactivity disorder. J Transcult Nurs. 2005;16(4): 312-321
70. DosReis S, Mychailyszyn MP, Myers M, Riley AW. Coming to terms with ADHD: how urban African-American families come to seek care for their children. Psychiatr Serv. 2007;58(5):636-641
71. Olaniyan O, dosReis S, Garriett V, et al. Community perspectives of childhood behavioral problems and ADHD among African American parents. Ambul Pediatr. 2007;7(3):226-231
72. Guevara JP, Feudtner C, Romer D, et al. Fragmented care for innercity minority children with attention-deficit/hyperactivity disorder. Pediatrics. 2005;116(4):e512-e517.
73. Davidson JC, Ford DY. Perceptions of attention deficit hyperactivity disorder in one African American community. J Negro Educ. 2001;70(4): 264-274
74. DosReis S, Barksdale CL, Sherman A, Maloney K, Charach A. Stigmatizing experiences of parents of children with a new diagnosis of ADHD. Psychiatr Serv. 2010;61(8):811-816
75. Pescosolido BA, Perry BL, Martin JK, McLeod JD, Jensen PS. Stigmatizing attitudes and beliefs about treatment and psychiatric medications for children with mental illness. Psychiatr Serv. 2007;58(5): 613-618
76. McLeod JD, Fettes DL, Jensen PS, Pescosolido BA, Martin JK. Public knowledge, beliefs, and treatment preferences concerning attentiondeficit hyperactivity disorder. Psychiatr Serv. 2007;58(5):626-631
77. Bowen J, Fenton T, Rappaport L. Stimulant medication and attention deficit-hyperactivity disorder. The child's perspective. Am J Dis Child. 1991;145(3):291-295
78. Sleator EK, Ullmann RK, von Neumann A. How do hyperactive children feel about taking stimulants and will they tell the doctor? Clin Pediatr (Phila). 1982;21(8):474-479
79. Kendall J, Hatton D, Beckett A, Leo M. Children's accounts of attentiondeficit/ hyperactivity disorder. ANS Adv Nurs Sci. 2003;26(2):114-130
80. Hoza B, Gerdes AC, Hinshaw SP, et al. Self-perceptions of competence in children with ADHD and comparison children. J Consult Clin Psychol. 2004;72(3):382-391
81. Hoza B, Owens JS, Pelham WE, et al. Parent cognitions as predictors of child treatment response in attention-deficit/hyperactivity disorder. J Abnorm Child Psychol. 2000;28(6):569-583
82. Hoza B, Pelham WE Jr, Dobbs J, Owens JS, Pillow DR. Do boys with attention-deficit/hyperactivity disorder have positive illusory self- concepts? J Abnorm Psychol. 2002;111(2):268-278
83. Hoza B, Pelham WE, Milich R, Pillow D, McBride K. The self- perceptions and attributions of attention deficit hyperactivity disordered and nonreferred boys. J Abnorm Child Psychol. 1993;21(3):271-286
84. Owens JS, Goldfine ME, Evangelista NM, Hoza B, Kaiser NM. A critical review of self-perceptions and the positive illusory bias in children with ADHD. Clin Child Fam Psychol Rev. 2007;10(4):335-351
85. Owens JS, Hoza B. The role of inattention and hyperactivity/impulsivity in the positive illusory bias. J Consult Clin Psychol. 2003;71(4):680-691
86. Pelham WE, Hoza B, Pillow DR, et al. Effects of methylphenidate and expectancy on children with ADHD: behavior, academic performance, and attributions in a summer treatment program and regular classroom settings. J Consult Clin Psychol. 2002;70(2):320-335
87. Efron D, Jarman FC, Barker MJ. Child and parent perceptions of stimulant medication treatment in attention deficit hyperactivity disorder. J Paediatr Child Health. 1998;34(3):288-292
88. Thiruchelvam D, Charach A, Schachar RJ. Moderators and mediators of long-term adherence to stimulant treatment in children with ADHD. J Am Acad Child Adolesc Psychiatry. 2001;40(8):922-928
89. Firestone P. Factors associated with children's adherence to stimulant medication. Am J Orthopsychiatry. 1982;52(3):447-457
90. Meaux JB, Hester C, Smith B, Shoptaw A. Stimulant medications: a trade-off? The lived experience of adolescents with ADHD. J Spec Pediatr Nurs. 2006;11(4):214-226
91. Knipp DK. Teens' perceptions about attention deficit/hyperactivity disorder and medications. J Sch Nurs. 2006;22(2):120-125
92. Bussing R, Zima BT, Mason D, Hou W, Garvan CW, Forness S. Use and persistence of pharmacotherapy for elementary school students with attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol. 2005;15(1):78-87
93. Giacomini MK, Cook DJ. Users' guides to the medical literature: XXIII. Qualitative research in health care A. Are the results of the study valid? Evidence-Based Medicine Working Group. JAMA. 2000;284(3): 357-362
94. Wagner EH, Austin BT, von Korff M. Organizing care for patients with chronic illness. Milbank Q. 1996;74(4):511-544
95. O'Connor AM, Llewellyn-Thomas HA, Flood AB. Modifying unwarranted variations in health care: shared decision making using patient decision aids. Health Aff (Millwood). 2004;Suppl Web Exclusives: VAR63-VAR72.
96. Epstein JN, Langberg JM, Lichtenstein PK, Mainwaring BA, Luzader CP, Stark LJ. Community-wide intervention to improve the attention-deficit/hyperactivity disorder assessment and treatment practices of community physicians. Pediatrics. 2008;122(1):19-27
97. Homer CJ, Horvitz L, Heinrich P, Forbes P, Lesneski C, Phillips J. Improving care for children with attention deficit hyperactivity disorder: assessing the impact of self-assessment and targeted training on practice performance. Ambul Pediatr. 2004;4(5):436-441
98. Doran GT. There's a S.M.A.R.T. way to write management's goals and objectives. Manage Rev. 1981;70(11):35-36
99. Hart CN, Kelleher KJ, Drotar D, Scholle SH. Parent-provider communication and parental satisfaction with care of children with psychosocial problems. Patient Educ Couns. 2007;68(2):179-185
100. Klassen AF, Miller A, Fine S. Health-related quality of life in children and adolescents who have a diagnosis of attention-deficit/hyperactivity disorder. Pediatrics. 2004;114(5):e541-e547.
101. Perwien AR, Faries DE, Kratochvil CJ, Sumner CR, Kelsey DK, Allen AJ. Improvement in health-related quality of life in children with ADHD: an analysis of placebo controlled studies of atomoxetine. J Dev Behav Pediatr. 2004;25(4):264-271
102. Perwien AR, Kratochvil CJ, Faries DE, Vaughan BS, Spencer T, Brown RT. Atomoxetine treatment in children and adolescents with attention-deficit hyperactivity disorder: what are the long-term healthrelated quality-of-life outcomes? J Child Adolesc Psychopharmacol. 2006;16(6):713-724
103. Rentz AM, Matza LS, Secnik K, Swensen A, Revicki DA. Psychometric validation of the child health questionnaire (CHQ) in a sample of children and adolescents with attention-deficit/hyperactivity disorder. Qual Life Res. 2005;14(3):719-734
104. Sawyer MG, Whaites L, Rey JM, Hazell PL, Graetz BW, Baghurst P. Health-related quality of life of children and adolescents with mental disorders. J Am Acad Child Adolesc Psychiatry. 2002;41(5): 530-537
105. Varni JW, Burwinkle TM. The PedsQL as a patient-reported outcome in children and adolescents with attention-deficit/hyperactivity disorder: a population-based study. Health Qual Life Outcomes. 2006;4:26.
106. Epstein JN, Langberg JM, Lichtenstein PK, et al. Attention-deficit/hyperactivity disorder outcomes for children treated in communitybased pediatric settings. Arch Pediatr Adolesc Med. 2010;164(2): 160-165
107. Saylor KE, Buermeyer CM, Spencer TJ, Barkley RA. Adaptive changes related to medication treatment of ADHD: listening to parents of children in clinical trials of a novel nonstimulant medication. J Clin Psychiatry. 2002;63 Suppl 12:23-28
108. Cunningham CE. A family-centered approach to planning and measuring the outcome of interventions for children with attention-deficit/hyperactivity disorder. Ambul Pediatr. 2007;7(1 Suppl):60-72
109. Swanson J, Arnold LE, Kraemer H, et al. Evidence, interpretation, and qualification from multiple reports of long-term outcomes in the Multimodal Treatment Study of children with ADHD (MTA): Part II: supporting details. J Atten Disord. 2008;12(1):15-43